Here are four things to know:
1. Emergency BioSolutions was well-known for creating vaccines to fight Anthrax in 2002. The company also received a $220 million government contract in 2012 to devise an Ebola vaccine.
2. The company will work to develop and manufacture a drug to fight Zika, pending FDA approval. However, the agency may give the vaccine an “emergency use authorization” designation to quicken the approval process and allow for clinical trails by early next year.
3. Barbara Solow, Emergent’s head of research and development, said their vaccine so far has shown proof of concept during animal testing.
4. No Zika vaccines are available on the market, despite the virus erupting in 46 countries since 2015.
More articles on quality & infection control:
CDC awards $226M to 5 academic centers for patient safety efforts: 5 notes
Texas & Florida lack funding to launch substantial Zika prevention awareness among pregnant women: 4 insights
Obama administration rejects House $1.1B Zika bill: 4 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
